Aman Chauhan, Kelley Chan, Thorvardur R Halfdanarson, Andrew M Bellizzi, Guido Rindi, Dermot O'Toole, Phillip S Ge, Dhanpat Jain, Arvind Dasari, Daniel A Anaya, Emily Bergsland, Erik Mittra, Alice C Wei, Thomas A Hope, Ayse T Kendi, Samantha M Thomas, Sherlonda Flem, James Brierley, Elliot A Asare, Kay Washington, Chanjuan Shi
The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to each staging system. GEP-NETs are the second most prevalent neoplasm of gastrointestinal origin after colorectal cancer. Since publication of the AJCC eighth edition, the World Health Organization has updated the classification and separates grade 3 GEP-NETs from poorly differentiated neuroendocrine carcinoma...
April 29, 2024: CA: a Cancer Journal for Clinicians